A Phase 2 Study To Evaluate The Efficacy And Safety Of MK-1026 In Participants With Hematologic Malignancies Read more
“Retrospective Review Of Outcomes And Prognostic Factors Of Patients With COVID-19 Infection And Lymphoid Malignancy” Read more
An Open-Label Study To Assess The Anti-Tumor Activity And Safety Of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Antibody, In Patients With Relapsed Or Refractory Follicular Lymphoma Read more
A Phase 2 Study To Assess The Safety And Efficacy Of TGR-1202 In Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant To Prior BTK (Bruton Tyrosine Kinase) Or PI3K-Delta (Phosphoinositide-3-Kinase) Inhibitor Therapy Read more
A Phase 2 Study To Assess The Efficacy And Safety Of TGR-1202 (Umbralisib) Monotherapy In Patients With Non-Follicular Indolent Non-Hodgkin?S Lymphoma Read more
A Phase 2 Multi-Center Study Evaluating The Safety And Efficacy Of CD30-Directed Genetically Modified Autologous T Cells (CD30.CAR-T) In Adult And Pediatric Patients With Relapsed Or Refractory CD30 Positive Classical Hodgkin Lymphoma (CHARIOT TESSCAR001) Read more
A Phase 1/1b Open-Label Dose Escalation And Expansion Study Of Bcl-2 Inhibitor BGB-11417 In Patients With Mature B-Cell Malignancies Read more
A Phase 1a/1b Dose Escalation And Expansion Trial Of TTI-621, A Novel Biologic Targeting CD47, In Subjects With Relapsed Or Refractory Hematologic Malignancies And Selected Solid Tumors Read more
A Phase 2, Multicenter, Single-Arm Study Of Zanubrutinib (BGB-3111) In Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant Of Prior Treatment With Ibrutinib Read more
